-T M Allen Researcher Activity Profile

Research Author Detailed Information 

T M Allen Publication Rate By Year

T M Allen has published 4 paper(s) in 2006, 17 paper(s) in 2007, 9 paper(s) in 2008, for a total of 30 research publications in total.

T M Tm Allen Author Information

LAST NAME: allen

FIRST NAME: T M

INITIALS: tm

AFFILIATION:

Papers

T M Allen's Publication Record

1. Characterization of full-length hepatitis C virus genotype 4 sequences. Year Published: 2007
Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
2. Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Year Published: 2006
Program for Research in Smokers with Mental Illness (PRISM), Yale University School of Medicine, New Haven, CT 06519, USA. kristi.sacco@yale.edu
3. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Year Published: 2006
Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, Substance Abuse Center, Connecticut Mental Health Center, New Haven, CT 06519, USA. tony.george@utoronto.ca
4. Year Published: 2006
Program for Research on Smokers with Mental Illness, Yale University School of Medicine, New Haven, CT 06511, USA. andrea.weinberger@yale.edu
5. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. Year Published: 2006
Partners AIDS Research Center, MGH-East, CNY 6616, 149 13th Street, Charlestown, MA 02129, USA.
6. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Room 5212, Charlestown, MA 02129, USA.
7. Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Year Published: 2007
Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. julianszw@gmail.com
8. Viral sequence evolution in acute hepatitis C virus infection. Year Published: 2007
Massachusetts General Hospital, Infectious Disease, 13th Street, Charlestown, MA 02129, USA.
9. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital-East, CNY 6625, Charlestown, MA 02129, USA.
10. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
11. Increased sequence diversity coverage improves detection of HIV-specific T cell responses. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
12. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Year Published: 2007
13. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. Year Published: 2007
Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02129, USA.
14. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, and Harvard University Center for AIDS Research, Boston, MA 02129, USA.
15. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Year Published: 2007
16. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital-East, CNY 6625, Charlestown, MA 02129, USA.
17. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
18. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. Year Published: 2007
Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02129, USA.
19. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, and Harvard University Center for AIDS Research, Boston, MA 02129, USA.
20. Increased sequence diversity coverage improves detection of HIV-specific T cell responses. Year Published: 2007
Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
21. Ligand-targeted liposomal therapies of neuroblastoma. Year Published: 2008
Differentiation Therapy Unit, Laboratory of Oncology, G. Gaslini Children's Hospital, Genoa, Italy. mircoponzoni@ospedale-gaslini.ge.it.
22. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. Year Published: 2008
Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
23. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. Year Published: 2008
Differentiation Therapy Unit, Laboratory of Oncology, G. Gaslini Children's Hospital, 16148-Genoa, Italy.
24. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. Year Published: 2008
Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
25. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. Year Published: 2008
Differentiation Therapy Unit, Laboratory of Oncology, G. Gaslini Children's Hospital, 16148-Genoa, Italy. fabiopastorino@ospedale-gaslini.ge.it
26. Ligand-targeted liposomal therapies of neuroblastoma. Year Published: 2008
Differentiation Therapy Unit, Laboratory of Oncology, G. Gaslini Children's Hospital, Genoa, Italy.
27. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Year Published: 2007
Department of Biochemistry, University of Zürich, Zürich, Switzerland.
28. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. Year Published: 2008
Massachusetts General Hospital and Harvard Medical School, Partners AIDS Research Center, MGH East no. 5239, 149 13th St., Charlestown, MA 02143, USA.
29. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. Year Published: 2008
Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
30. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. Year Published: 2008
Differentiation Therapy Unit, Laboratory of Oncology, G. Gaslini Children's Hospital, 16148-Genoa, Italy. fabiopastorino@ospedale-gaslini.ge.it